Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"

   Hotel Registration
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Wissenschaftliches Programm
   Scientific program
   Poster Presentation
Begleitende Veranstaltungen
   Accompanying program
   Working sessions
   Social program
Allgemeine Informationen
   General Information
   Index of Authors
   Commercial exhibitors

DOG Homepage


Intraocular Pressure after Intravitreal Injection of Triamcinolone Acetonide

Kreissig I., Jonas J. B., Degenring R.
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg

Purpose: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or edematous diseases.
Method: The prospective consecutive non-comparative interventional case-series study included 71 patients (75 eyes) with progressive exudative age-related macular degeneration (n=64 eyes) or diffuse diabetic macular edema (n=11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow-up time was 6.86 ± 2.52 months (range, 3.1-14.47 months).
Results: Intraocular pressure increased significantly (P<0.001) from 15.43 ± 3.26 mm Hg preoperatively to a mean maximum of 23.38 ± 8.37 mm Hg (range, 13 – 64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about two months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalized about six months after the injection, without further medication. Eyes undergoing repeatedl

Zurück | Back